Close
Close
Treatment News

Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

4.0
4.0 from 2 votes
Friday, October 19, 2018

PARIS, France - Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeting tumor DNA Damage Response (DDR) to fight resistant cancers, announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at the 2nd DNA Damage Response Therapeutics Summit (DDRTS) to be held January 29-31, 2019, in Boston, MA.

This leading industry summit provides the opportunity to gain exclusive insights on the latest innovations in the field of tumor DNA Damage Response. The presence of prominent pharmaceutical groups and research institutions testifies to the attractiveness of this rapidly growing field.

Onxeo will present an overview of AsiDNA™, the Company's first-in-class compound targeting tumor DNA break repair pathways, during a session entitled, "New Developments in PARP Inhibitors & Novel DDR Pathway Targets."

Françoise Bono, Chief Scientific Officer of Onxeo, said: "AsiDNA™ has shown unique properties in translational research, notably its ability to prevent resistance to PARP inhibitors and to potentiate their activity in cancer cells, regardless of genetic mutation status. Its strong synergy with DNA-damaging agents, such as chemotherapies and PARP inhibitors, could also open new therapeutic options in difficult-to-treat cancers. We are pleased to have been selected to present at this benchmark event among the world's most recognized stakeholders in DNA Damage Response. This is the ideal forum to update the industry, scientific and clinical experts on the recent clinical development progress achieved with AsiDNA™, a highly-differentiated molecule acting upstream of multiple DNA damage response pathways."

Session: New Developments in PARP Inhibitors & Novel DDR Pathway Targets

Date: Wednesday, January 30, 2019

Time: 2:00 pm

Location: Revere Hotel Boston Common, 200 Stuart St., Boston, MA 02116

Onxeo's presentation: AsiDNA™, A First-in-Class Decoy Oligonucleotide Targeting DNA Repair to Kill Tumor Cells

  • AsiDNA™ is an innovative global DNA damage response inhibitor preventing recruitment of enzymes involved in DSB and SSB repair at the damage site
  • AsiDNA™ is synergistic with PARP inhibitors, prevents and reverses PARPi-acquired resistance
  • Recent outcomes from the phase 1 clinical study of AsiDNA™
     

For further information, please visit the DNA Damage Response Therapeutics Summit website.

About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo is developing AsiDNA™, a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a unique decoy & agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the unique properties of AsiDNA™, notably its ability to oppose and even reverse tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. AsiDNA™ is currently being evaluated for systemic (IV) administration in advanced solid tumors in the DRIIV-1 phase I study (DNA Repair Inhibitor administered IntraVenously).

AsiDNA™ is the first compound generated from platON™, the Company's proprietary chemistry platform of decoy oligonucleotides dedicated to generate new innovative leads and broaden Onxeo's pipeline.

Onxeo's portfolio also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).

For further information, please visit www.onxeo.com.

Contacts:
Onxeo
Valérie Leroy
Investor relations
Phone nb.: +33 1 45 58 76 00
Email: investors@onxeo.com

NewCap
Dusan Oresansky / Emmanuel Huynh
Investor Relations / Strategic Communications
Phone nb.: +33 1 44 71 94 92
Email: onxeo@newcap.eu

Alize RP
Caroline Carmagnol / Tatiana Vieira
Media Relations
Phone nb.: +33 (0) 1 44 54 36 65
Email: alize-onxeo@alizerp.com

LifeSci Advisors
Brian Ritchie
Investor Relations US
Phone nb.: +1 212 915 2578
Email: britchie@lifesciadvisors.com

Source: Onxeo
4.0
4.0 from 2 votes
Free Newsletter
Videos
by Abidemi Uruejoma
11 views
by Abidemi Uruejoma
41 views
by Abidemi Uruejoma
56 views
by Abidemi Uruejoma
79 views